Bacteremia (blood culture)
bacteremia, anthrax, toxemia
ANTHRAX, RECURRENCE, PATHOLOGY, TOXEMIA, COMPLICATIONS
Before treatment, 69% of the IGIV group, 69% of the 7.5 U/kg dose group, 88% of the 15 U/kg dose group and 63% of the 30 U/kg dose group were bacteremic. On Day 24, one non-surviving animal in the 7.5 U/kg dose group exhibited complications with the telemetry implant, with no attribution to anthrax based on pathology results. Two animals in the 30 U/kg dose group were not bacteremic by blood culture at treatment and were excluded from survival analysis.IGIV-treated animals had significantly higher bacteremia rates than animals treated with 30 U/kg ANTHRASIL at all time points tested (p ≤ 0.0101). IGIV-treated groups also had higher bacteremia rates from 12 to 30 hours post-treatment and from 12 to 24 hours post-treatment than the groups treated with the 15 U/kg (p ≤ 0.0304) and 7.5 U/kg of ANTHRASIL (p = 0.0242), respectively.In contrast to toxemia data, post-treatment recurrence of bacteremia did not differ remarkably between the three dose levels of ANTHRASIL. Approximately 50% of animals treated with 7.5 or 15 U/kg ANTHRASIL exhibited recurrence of bacteremia compared to 70% of animals treated with 30 U/kg ANTHRASIL, despite enhanced survival with higher ANTHRASIL doses.